Results 41 to 50 of about 487,201 (201)
Background Although reduction in the JAK2V617F allele burden (%V617F) has been suggested as a criterion for defining disease response to cytoreductive therapy in polycythemia vera, its value as a response monitor is unclear.
Emil Kuriakose +7 more
doaj +1 more source
BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon
Leonardo Caires dos Santos +5 more
doaj +1 more source
Treatment of polycythemia vera [PDF]
Polycythemia vera is a chronic myeloproliferative neoplasm characterized by hematopoietic stem cell-derived clonal myeloproliferation resulting in erythrocytosis, leukocytosis and thrombocytosis. Survival is reduced compared with general population.
openaire +2 more sources
An image from a peripheral blood smear showing a thick smear with an abundant amount of red blood cells and platelets often seen in patients with polycythemia vera (50X oil immersion)
To, Michelle, Kwon, Gloria
core +1 more source
An image from a peripheral blood smear showing a thick smear with an abundant amount of red blood cells and platelets often seen in patients with polycythemia vera (50X oil immersion). A neutrophil is also present (center)
To, Michelle, Kwon, Gloria
core +1 more source
Polycythemia vera as a presentation of renal angiomyolipoma: a case report
Introduction Angiomyolipoma is a common benign renal tumor composed of thick-walled blood vessels, smooth muscle, and adipose tissue. It may be found incidentally during workup for suspected renal disease.
Lin Ming-Shyan +7 more
doaj +1 more source
CME: Polycythemia vera, myeloproliferative Neoplasie
Zusammenfassung. Zusammenfassung: Myeloproliferative Neoplasien (MPN) nach den Kriterien der WHO 2016 [1] stellen eine heterogene Krankheitsgruppe dar, die durch Proliferation einer oder mehrerer hämatopoietischer Zellreihen definiert ist.
Esther Bächli, Micha Gundelfinger
core +1 more source
We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon-α2 (PEG-IFNα2).
Anders Lindholm Sørensen +19 more
doaj +1 more source
Parathyroid Adenoma as a Rare Cause of Persistent Hypercalcemia in a Female with Polycythemia Vera
Polycythemia vera is one of the myeloproliferative neoplasms that is distinguished by the uncontrolled production of blood cells and an increased red cell mass due to acquired JAK2 mutation.
Ahmed M. Abdalhadi, Mohamed A. Yassin
doaj +1 more source
Studies of JAK2 mutations in myeloproliferative disorders [PDF]
Myeloproliferative disorders (MPD) are diseases characterized by clonal hematopoiesis with overprodution of mature cells from erythroid, megakaryocytic and myeloid lineages.
Li, Sai
core +1 more source

